Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Werfen Unveils Next Generation Hemostasis Testing Systems

By LabMedica International staff writers
Posted on 30 Jul 2025

Werfen (Barcelona, Spain) is unveiling the next generation of market-leading ACL TOP hemostasis testing systems at the ADLM Annual Meeting 2025, reinforcing the company’s commitment to innovation in specialized diagnostics. More...

Werfen also has announced the expansion of its award-winning Gem Premier 7000 with iQM3 to Europe, following its strong clinical adoption in North America.

Werfen had recently announced the commercialization of ACL TOP Family 70 Series hemostasis testing systems in North America, following 510(k) clearance by the US Food and Drug Administration and licensure by Health Canada. Building upon the company’s established legacy of quality and innovation in hemostasis testing, the ACL TOP Family 70 series hemostasis testing systems optimize workflow with a powerful combination of quality and efficiency, and connectivity across an entire laboratory network. To streamline and optimize workflow, ACL TOP Family 70 Series systems offer centralized QC and automated performance verification management. When connected to HemoHub Intelligent Data Manager, synergistic integration allows uniform application of a laboratory’s Quality Management System across multiple instruments and sites, from one centralized location; transcription errors are eliminated, and report generation and storage are automated. Performance verification studies that previously involved several manual processes are reduced to two automated steps, saving significant staff time, improving quality, and reducing costs.

At ADLM 2025, Werfen has announced the expanded commercialization for the GEM Premier 7000 with iQM3, following its early success in North America. Building on strong clinical adoption and recognition in the United States, the system is now available in Europe. The GEM Premier 7000 is the first blood gas testing system to integrate hemolysis detection at the point of care, addressing the most common preanalytical error in blood gas testing. The system earned five prestigious industry awards, including the 2025 Edison Award and Premier Inc. Supplier Innovation Award, for its groundbreaking integration of hemolysis detection at the point of care. These honors highlight its innovation, quality, and positive impact on clinical workflows and patient care.

Related Links:
Werfen


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.